Conduit Pharmaceuticals Inc. (CDT) - Bathi pungkasan

Conduit Pharmaceuticals is developing a portfolio of renal pathology treatments, mitigating risks through licensing agreements. The strategy is based on refining abandoned molecules from third-party tech giants. Conduit Pharmaceuticals aims to outperform global players in the treatment of autoimmune disorders. The current metric value is -0.04, which is clearly reflected in the company's accumulated profit trend.

Conduit Pharmaceuticals (CDT) monetizes its intellectual property through molecule licensing, where net income reflects the actual cash balance after deducting all operating expenses. By analyzing changes in the company's profit, an investor can filter out market volatility and identify one-time payments to avoid overpaying for the asset and objectively assess the sustainability of the business model based on fundamental indicators.